跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KDR-2-2
首页
药物
KDR-2-2
KDR-2-2
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Human anti-VEGFR-2/KDR antibodies
申请人: KADMON CORP LLC
优先权: 2012
CN
US
5 件公开
HUMAN ANTI-VEGFR-2/KDR ANTIBODIES
申请人: KADMON CORP LLC
优先权: 2014
CN
EP
US
WO
9 件公开
Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
申请人: GOV OF THE USA AS REPRESENTED
优先权: 2006
US
3 件公开
Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR)
申请人: BIOTECHNOLOGISCHE GES
优先权: 2000
EP
RECOMBINANT ANTIBODY STRUCTURES BINDING TO AND BLOCKING THE ACTIVITY OF VASCULAR ENDOTHELIAL GROWTH FACTOR 2 (VEGFR- 2/KDR)
申请人: ERDAG BERRIN
优先权: 2010
CN
US
3 件公开
COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER
申请人: MEDIMMUNE LTD
优先权: 2005
CN
EP
US
6 件公开
KDR siRNA and application thereof
申请人: YINLIN GE
优先权: 2008
CN
Medicinal usage of kuhseng extractive
申请人: HEJIHUANGPU MEDICINES SHANGHAI
优先权: 2006
CN
药物
反馈